Austedo vs Ingrezza

How they're similar

The similarities are the whole reason these two are usually discussed together.

• Same mechanism. Both inhibit VMAT2, which reduces the packaging of dopamine into vesicles for release from nerve terminals. Less dopamine release in movement pathways calms the abnormal movements of TD.
• Same target condition. Both are FDA-approved for tardive dyskinesia in adults. Valbenazine (Ingrezza) is also approved for chorea associated with Huntington's disease. Deutetrabenazine (Austedo) is approved for both TD and Huntington's chorea.
• Similar effectiveness. Trials show both reduce the Abnormal Involuntary Movement Scale (AIMS) score by roughly 30 to 50 percent from baseline. Head-to-head comparisons don't exist, but indirect comparisons suggest broadly similar performance.
• Similar timeline. Both work gradually. A meaningful reduction in movements usually shows within 4 to 8 weeks. It isn't an immediate change.
• Both are dosed once daily now. Ingrezza has always been once daily. Austedo was twice daily originally, but Austedo XR now offers a once-daily extended-release version.
• Both share the same core side effects. Sedation, akathisia (an inner restlessness), parkinsonism, and increased risk of falls in older adults.
• Both can prolong the QT interval on ECG. That matters for people with known long QT syndrome, certain heart rhythm conditions, or those taking other QT-prolonging medications.
• Both are metabolized in part by CYP2D6. Strong inhibitors of CYP2D6, like paroxetine, fluoxetine, or bupropion, can raise levels. That's usually managed with dose adjustments.
• Both carry a boxed warning about depression and suicidality. This is largely based on Huntington's disease studies rather than TD populations, but the warning applies to both indications.
• Both are extremely expensive. Cash prices run around $8,000 to $10,000 per month. Both are dispensed through specialty pharmacies, and both usually require prior authorization and manufacturer support programs to be affordable.
• Neither replaces addressing the cause of TD. When possible, adjusting the antipsychotic (lower dose, switch to a lower-risk agent, sometimes clozapine) is part of the picture.

How they differ

The differences are meaningful but not dramatic.

Deutetrabenazine is a deuterated version of tetrabenazine, an older VMAT2 inhibitor still used mostly for Huntington's chorea. Deuterium is a heavier form of hydrogen. Replacing certain hydrogen atoms with deuterium slows the drug's breakdown, which lets it be dosed less often and with a smoother blood-level curve than tetrabenazine. That's why Austedo is generally better tolerated than the older tetrabenazine.

Valbenazine is a different molecule, a prodrug that converts in the body to an active metabolite, alpha-HTBZ, which is one of the active pieces that tetrabenazine also produces. The design is meant to give more selective VMAT2 inhibition with less off-target activity, which some evidence suggests translates into fewer dopamine-related side effects than tetrabenazine.

Dosing convenience has shifted with Austedo XR. Original Austedo was twice daily with food, which added complexity. Austedo XR is once daily with food, which brings it much closer to Ingrezza's simplicity. Ingrezza has always been once daily, and it doesn't require being taken with food. For patients who struggle with medication schedules, once-daily dosing without food restrictions can matter.

Starter kits exist for both. Ingrezza's initial dose is 40 mg for the first week, then 80 mg for the target dose (though some patients respond to 40 or 60 mg). Austedo's titration is more gradual, going up by 6 mg per week (or 12 mg per week for XR) until either symptoms are controlled or the maximum dose is reached.

Boxed warning language is similar but the historical context is different. The depression and suicidality warning traces back to studies of tetrabenazine in Huntington's disease, where mood changes were frequent because Huntington's itself causes depression, and dopamine reduction can worsen it. In TD populations, the risk appears lower but the warning still applies. Both drugs carry this warning, and both need caution or avoidance in patients with active depression or a history of suicidality. Some clinicians treat active suicidal ideation as an absolute contraindication.

Side effect tendencies

Side effects overlap heavily, but small differences exist.

Sedation and somnolence show up with both. It can be dose-related, and taking Ingrezza at bedtime or Austedo XR at bedtime can help if daytime sleepiness is a problem.

Akathisia is a restlessness that can feel like an urge to move, pace, or shift constantly. It happens with both, and it's paradoxical because the drug is meant to reduce abnormal movements. If it appears, dose reduction usually helps.

Parkinsonism (slowness, stiffness, resting tremor) is possible with both because reducing dopamine transmission is what they do. Dose reduction is the fix.

Depression and suicidal thinking are the most concerning side effects. Both drugs carry the boxed warning. In practice, careful screening for baseline mood before starting, and regular check-ins during treatment, are standard. A person with active depression, or a recent history of suicidal thinking, usually isn't a candidate for either.

Falls in older adults are worth thinking about because of sedation and parkinsonism. Balance monitoring and dose adjustment are reasonable.

QT prolongation is a class effect. Both drugs require caution in people with heart rhythm risks or on other QT-prolonging medications. A baseline ECG isn't always needed but is sometimes considered.

Nausea, headache, dry mouth, and fatigue are all common with both.

Neuroleptic malignant syndrome has been reported rarely with both, in the setting of concurrent antipsychotic use. This is a medical emergency with fever, rigidity, and mental status changes.

What tips the choice

Because the two are so closely matched, the deciding factors are usually practical.

Insurance formulary is the biggest driver. Both are expensive, both need prior authorization, and both have manufacturer support programs. Whichever one the insurance covers, or covers with less friction, is often where treatment starts.

Dosing simplicity used to favor Ingrezza clearly. With Austedo XR, that gap is narrower. Ingrezza still wins on food independence, but Austedo XR is once daily.

CYP2D6 metabolism matters when other medications interact. For Austedo, strong CYP2D6 inhibitors cap the dose lower. For Ingrezza, strong CYP2D6 inhibitors lower the target dose. Both need attention if the patient is on fluoxetine, paroxetine, or bupropion.

Prior response carries weight. If someone tried Ingrezza without adequate benefit or with intolerable side effects, trying Austedo (or vice versa) is reasonable. There's no cross-over data telling us how often people respond to one after failing the other, but clinical experience suggests some do.

Access to specialty pharmacy and manufacturer support programs varies by region and can affect which one is easier to actually get started.

Neither drug reverses the underlying vulnerability. If the antipsychotic causing TD can be safely lowered, changed to a lower-risk medication, or in some cases stopped, that conversation is worth having. Sometimes a switch to clozapine or quetiapine reduces TD without needing a VMAT2 inhibitor. That's a case-by-case decision.

Common questions

Do these medications cure tardive dyskinesia? No. They reduce the abnormal movements as long as they're taken. If the medication stops, the movements typically return over weeks. TD itself can improve over years for some people, especially if the offending antipsychotic is lowered or changed, but VMAT2 inhibitors are treatments rather than cures.

How quickly will I see improvement? Meaningful reduction in movements usually shows up within 4 to 8 weeks, with continued improvement over the following months. The first two weeks often show little change. Setting expectations early helps. Rapid improvement in the first few days isn't typical, and gradual progress is the norm.

Can I stay on my antipsychotic while taking one of these? Usually yes. Most people on Ingrezza or Austedo for TD are still taking the antipsychotic that caused it, because stopping the antipsychotic isn't safe for their underlying psychiatric condition. Whenever possible, discussing whether the antipsychotic dose can be lowered, or whether a lower-risk alternative would work, is worth doing. But VMAT2 inhibitors can be used alongside ongoing antipsychotic treatment.

Will these make my depression worse? That's the main concern that led to the boxed warning. In tardive dyskinesia populations, the depression risk appears lower than in Huntington's disease, but it's not zero. Anyone with a history of depression or suicidality needs careful screening before starting, and regular check-ins during treatment. If mood worsens, the medication is usually reduced or stopped.

Why are they so expensive? Both are brand-name drugs with no generics available yet. Their pricing reflects specialty drug economics, small patient populations, and complex manufacturing. Insurance coverage combined with manufacturer patient assistance programs makes them accessible for many, but out-of-pocket cost without insurance help is a barrier for a lot of people. Generic availability may change this in coming years.

Sources

This guide draws on current prescribing information and public health references. It is reviewed for clinical accuracy and updated as guidance changes. This is not medical advice.

1. U.S. Food and Drug Administration. Deutetrabenazine (Austedo, Austedo XR) prescribing information.
2. U.S. Food and Drug Administration. Valbenazine (Ingrezza) prescribing information.
3. American Psychiatric Association. Practice guideline for the treatment of patients with schizophrenia, tardive dyskinesia recommendations.
4. MedlinePlus, U.S. National Library of Medicine.